← Leaderboards
Victoria Wang
University Of California, San Francisco
$1,816,208
Attributed
$2,023,816
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $621.8K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,023,816 · 3
By mechanism
K08$1,233,450 · 1
R21$415,216 · 1
R01$375,150 · 1
Top collaborators
- Bradley Wayne Blaser2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Eric Collisson$14,159,893
- William A Weiss$31,543,847
- Andrew L Wolfe$1,146,361
- Natalia Jura$7,732,121
- Hua Su$11,193,749
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationMutationResistance MechanismBiologyCombined Modality TherapyClinical TrialsNovel TherapeuticsPathway InteractionsTumorPublishingAreaProteinsMediatingMolecularMortalityPrincipal InvestigatorProductionReportingAutocrineInhibitorGeneticImmuneGenetically Engineered MouseCytokine
Grant awards (8)
Mechanistic Dissection and Modulation of Cytoskeletal Regulation to Overcome Innate Resistance to KRAS Inhibition$375,150
R01 · FY2025 · CA · contact PI
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression$246,690
K08 · FY2025 · CA · contact PI
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression$246,690
K08 · FY2024 · CA · contact PI
Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML)$177,115
R21 · FY2024 · CA · contact PI
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression$246,690
K08 · FY2023 · CA · contact PI
Targeting Autocrine Hepatocyte Growth Factor (HGF) Production as a Therapeutic Modality in Acute Myeloid Leukemia (AML)$238,101
R21 · FY2023 · CA · contact PI
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression$246,690
K08 · FY2022 · CA · contact PI
Mechanistic Determination of KRAS Lung Cancer Regression upon CRAF Suppression$246,690
K08 · FY2020 · CA · contact PI